The microRNA landscape of cutaneous squamous cell carcinoma. Drug Discov Today 2018 Apr;23(4):864-870
Date
01/11/2018Pubmed ID
29317340DOI
10.1016/j.drudis.2018.01.023Scopus ID
2-s2.0-85044609537 (requires institutional sign-in at Scopus site) 30 CitationsAbstract
Cutaneous squamous cell carcinoma (cSCC) is a keratinocyte-derived skin tumor. It is the second-most-common cancer affecting the Caucasian population and is responsible for >20% of all skin-cancer-related deaths. The estimated incidence of non-melanoma skin cancer in the USA is >1000000 cases per year, of which roughly 20-30% are squamous cell carcinoma. To better understand and treat this challenging cancer, current research focuses on development of novel strategies to improve the understanding of tumor biogenesis on an individual basis. microRNAs are becoming important biomarkers in the diagnosis, prognosis and treatment of cSCC. This review describes the current knowledge on miRNA expression in cSCC and its role as a biomarker for personalized medicine.
Author List
Konicke K, López-Luna A, Muñoz-Carrillo JL, Servín-González LS, Flores-de la Torre A, Olasz E, Lazarova ZAuthor
Edit Olasz PhD, MD Associate Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBiomarkers, Tumor
Carcinoma, Squamous Cell
Humans
MicroRNAs
Prognosis
Skin Neoplasms
